@article{fdi:010066118,
  title = {{A}ssessment of a glycated hemoglobin point-of-care analyzer ({A}1{CN}ow+) in comparison with an immunoturbidimetric method : a diagnostic accuracy study},
  author = {{A}ffret, {A}. and {G}riz, {L}. {H}. {M}. and {C}esse, {E}. {A}. {P}. and {S}pecht, {Y}. {D}. and de {C}arvalho, {E}. {M}. {F}. and {F}ontbonne, {A}nnick},
  editor = {},
  language = {{ENG}},
  abstract = {{CONTEXT} {AND} {OBJECTIVE}: {T}o monitor glycemic control in diabetic patients, regular measurement of glycated hemoglobin ({H}b{A}1c) is recommended, but this can be difficult in remote places without access to laboratories. {P}ortable point-of-care testing devices can prove a useful alternative. {O}ur study aimed to assess the performance of one of them: {A}1{CN}ow+, from {B}ayer. {DESIGN} {AND} {SETTING}: {C}ross-sectional accuracy study conducted at a university hospital in {B}razil. {METHODS}: {W}e made three successive measurements of capillary {H}b{A}1c using the {A}1{CN}ow+ in 55 diabetic volunteers, while the same measurement was made on venous blood using the hospital reference method ({V}itros 5,1 {FS}). {W}e used the {B}land-{A}ltman graphical method to assess the {A}1{CN}ow+ in relation to the {V}itros 5,1 {FS} method. {W}e also evaluated clinical usefulness by calculating the sensitivity and specificity of {A}1{CN}ow+ for detecting patients with {H}b{A}1c lower than 7%, which is the usual limit for good glycemic control. {RESULTS}: {T}he coefficient of variation between repeat testing for the {A}1{CN}ow+ was 3.6%. {T}he mean difference between {A}1{CN}ow+ and {V}itros 5,1 {FS} was +0.67% (95% confidence interval, {CI}: +0.52 to +0.81). {T}he agreement limits of our {B}land-{A}ltman graph were -0.45 (95% {CI}: -0.71 to -0.19) and +1.82 (95% {CI}: +1.52 to +2.05). {T}he sensitivity and specificity in relation to the 7% limit were respectively 100% and 67.7%. {CONCLUSIONS}: {A}lthough the {A}1{CN}ow+ had good sensitivity, its accuracy was insufficient for use as a replacement for laboratory measurements of {H}b{A}1c, for glycemic control monitoring in diabetic patients.},
  keywords = {{H}emoglobin {A}, glycosylated ; {P}oint-of-care systems ; {T}echnology assessment, biomedical ; {D}iabetes mellitus ; {P}rimary health care ; {BRESIL}},
  booktitle = {},
  journal = {{S}ao {P}aulo {M}edical {J}ournal},
  volume = {133},
  numero = {6},
  pages = {460--464},
  ISSN = {1516-3180},
  year = {2015},
  DOI = {10.1590/1516-3180.2013.9110911},
  URL = {https://www.documentation.ird.fr/hor/fdi:010066118},
}